- Home
- / Mast Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Mast Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$257 K
FY, 2020
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 128.0K | 257.0K | |||||||||
| Revenue growth, % | -100.0% | ||||||||||
| General and administrative expense | 7.2M | 7.5M | 9.5M | 11.0M | 9.3M | 11.1M | 10.7M | 13.1M | 14.3M | 12.4M | |
| Operating expense total | 12.9M | 15.6M | 12.9M | 28.9M | 39.2M | 30.1M | 29.6M | 47.8M | 51.9M | 49.3M | |
| Depreciation and amortization | 85.0K | 146.0K | 99.0K | 363.0K | 526.0K | 311.0K | 255.0K | 136.0K | |||
| EBIT | (13.4M) | (15.6M) | (21.5M) | (29.3M) | (39.4M) | (36.5M) | (30.0M) | (70.0M) | (79.0M) | (49.3M) | (41.5M) |
| EBIT margin, % | -28481.2% | -19182.9% | |||||||||
| Interest income | 76.6K | 73.6K | 60.3K | 69.0K | 130.0K | 122.0K | |||||
| Interest expense | 11.0K | 11.0K | 70.0K | 1.5M | (2.3M) | ||||||
| Pre tax profit | (21.5M) | (38.5M) | (33.4M) | (70.0M) | (78.2M) | (49.6M) | (43.0M) | ||||
| Income tax expense | (2.4M) | (3.6M) | (8.5M) | ||||||||
| Net Income | (13.3M) | (15.6M) | (21.5M) | (28.7M) | (39.8M) | (36.1M) | (29.8M) | (61.5M) | (78.2M) | (49.6M) | (43.0M) |